FAQ on Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results and Rare Disease Pipeline Progress

What are the key highlights from Soligenix’s Q2 2025 results?

Key highlights include the expectation of top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, active enrollment in a confirmatory Phase 3 trial of HyBryte(TM) for early-stage CTCL with results anticipated in 2026, and completion of a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease.

What is HyBryte(TM) and what is its significance?

HyBryte(TM) (SGX301 or synthetic hypericin) is a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), representing a significant advancement in treating this rare disease with potential worldwide commercialization following regulatory approvals.

How did Soligenix perform financially in Q2 2025?

Soligenix reported a net loss of $2.7 million, or ($0.82) per share, with R&D expenses rising to $1.7 million due to higher trial and manufacturing costs, and cash reserves of $5.1 million as of June 30, 2025, plus an additional $1.4 million raised on July 1.

What are the upcoming milestones for Soligenix?

Upcoming milestones include the release of top-line Phase 2a results for SGX302 in psoriasis before year-end and the anticipated results of the confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL in 2026.

Where can I find more information about Soligenix and its projects?

More information can be found on Soligenix’s website at www.Soligenix.com and the latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.

What is the significance of Soligenix’s partnership with Sterling Pharma Solutions?

The partnership facilitated the transfer of manufacturing of synthetic hypericin to the U.S., supporting Soligenix’s development and commercialization efforts for its photodynamic therapy treatments.

What diseases is Soligenix focusing on?

Soligenix is focusing on rare diseases with unmet medical needs, including cutaneous T-cell lymphoma (CTCL), psoriasis, Behçet’s Disease, inflammatory diseases, and vaccine programs for ricin toxin, filoviruses, and COVID-19.

How is Soligenix funding its operations?

Soligenix is funding its operations through its cash reserves, which stood at $5.1 million on June 30, 2025, plus $1.4 million raised on July 1, and has been supported by government grants and contract funding from NIAID, DTRA, and BARDA for its Public Health Solutions business segment.